��ɫ��Ƶ

Stryker recently announced the commercial launch of the Surpass Elite Flow Diverter in the United States, South Korea and ��ɫ��Ƶ. This next-generation device represents a significant advancement in flow diversion, combining an upgraded implant design with a proprietary surface modification for enhanced performance and reduced thrombin generation.

Surpass Elite Flow Diverter introduces BioStealth Surface, a new surface modification developed through a proprietary neutralisation process that creates a more thromboresistant cobalt chromium and is backed by both in vitro and in vivo studies.

Surpass Elite Flow Diverter also introduces a fundamentally improved implant design—engineered with a higher braid angle and optimised heat treatment to enable better opening, improved vessel-wall apposition, and reduced manipulation during deployment. These enhancements address common procedural challenges physicians face in flow diversion, helping streamline deployment and build confidence in complex cases.

“Surpass Elite Flow Diverter captures the essence of a cobalt chromium device, delivering outstanding performance and exceptional ease of use,” noted Dr. Alejandro Tomasello, Vall d'Hebron University Hospital, Barcelona, Spain.

This blend of innovation and usability is echoed by others with firsthand experience and deep familiarity with the device.

“I have been fortunate to be part of the development of the Surpass Elite Flow Diverter, Stryker’s most sophisticated flow-diverting stent to date,” said Dr. Alex Coon, Carondelet Neurological Institute, Tucson, Arizona. “My early experience suggests that this device gives physicians the exact blend of device opening, vessel-wall apposition, and surface treatment for which we have all been waiting a decade.”

Surpass Elite Flow Diverter received FDA approval and CE Mark in 2024. Stryker implemented a measured rollout focused on physician training and real-world clinical validation before scaling commercially.

“This cadenced launch strategy reflects our commitment to clinical excellence,” said Jim Marucci, president of Stryker’s Neurovascular division. “After carefully validating performance across a diverse set of early cases, we’re pleased to move to this next step and help address unmet customer needs.”

Now commercially available, Surpass Elite Flow Diverter delivers the latest in surface science and implant design.

For more information on the Surpass Elite Flow Diverter:
For US HCPs visit: Surpass Elite Flow Diverter_US
For OUS HCPs visit: Surpass Elite Flow Diverter_OUS